Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Income towards Parent Company: 2020-2025

Historic Income towards Parent Company for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to -$52.9 million.

  • Rhythm Pharmaceuticals' Income towards Parent Company fell 21.23% to -$52.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$192.3 million, marking a year-over-year increase of 25.72%. This contributed to the annual value of -$260.6 million for FY2024, which is 41.11% down from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Income towards Parent Company stood at -$52.9 million for Q3 2025, which was down 13.45% from -$46.6 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Income towards Parent Company peaked at $43.8 million during Q1 2021, and registered a low of -$141.4 million during Q1 2024.
  • For the 3-year period, Rhythm Pharmaceuticals' Income towards Parent Company averaged around -$54.0 million, with its median value being -$46.6 million (2025).
  • Its Income towards Parent Company has fluctuated over the past 5 years, first surged by 228.06% in 2021, then slumped by 220.07% in 2022.
  • Over the past 5 years, Rhythm Pharmaceuticals' Income towards Parent Company (Quarterly) stood at -$50.9 million in 2021, then grew by 16.44% to -$42.5 million in 2022, then grew by 2.02% to -$41.6 million in 2023, then decreased by 3.98% to -$43.3 million in 2024, then fell by 21.23% to -$52.9 million in 2025.
  • Its last three reported values are -$52.9 million in Q3 2025, -$46.6 million for Q2 2025, and -$49.5 million during Q1 2025.